Developing a new treatment to enhance radiation therapy and boost the immune response in lung cancer
Official title: Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC
Funded at Ut Southwestern Medical Center · NIH-11078323 · Data updated 2026-11-12
This study is testing a new oral medication for people with non-small cell lung cancer that helps make cancer cells more vulnerable to radiation and immune therapy, aiming to improve treatment results for those who haven't had success with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $551,399 |
| NIH project number | 5R01CA276058-03 |
| Project ID | NIH-11078323 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing radiation therapy or immunotherapy.
✕Less likely to help
Patients with other types of lung cancer or those who are not receiving radiation therapy or immunotherapy may not benefit from this research.
What this research studies
This research focuses on improving treatment outcomes for patients with non-small cell lung cancer (NSCLC) by developing a new oral medication that inhibits specific proteins involved in DNA repair. By blocking these proteins, the treatment aims to make cancer cells more sensitive to radiation therapy and enhance the effectiveness of immune checkpoint inhibitors. The approach seeks to address the limitations of current therapies, particularly in patients who do not respond well to existing treatments. Patients may benefit from a more effective combination of radiation and immunotherapy, potentially leading to better survival rates.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for lung cancer patients, increasing their chances of survival and reducing recurrence rates.
How similar studies have gone: Previous research has shown promise in using similar approaches to enhance the effectiveness of cancer treatments, indicating potential for success in this novel strategy.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Kittler, Ralf — Ut Southwestern Medical Center
- Study coordinator: Kittler, Ralf
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.